| Document |
Document Title |
|
WO/2022/092180A1 |
To solve a food crisis associated with an increase in world population expected in the near future, the creation of novel herbicides having high safety for crops and excellent herbicidal activity against weeds is desired. The problem is ...
|
|
WO/2022/092247A1 |
The present inventors found a novel method of reducing a formyl group with the use of a Lewis acid and a hydride reducing agent in a production process of a 3-methyl-4-halo-indole derivative. Further, the present inventors found that dem...
|
|
WO/2022/084448A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, R4, R4a, R4b, R4c, R4d, R4e, R5, R6 have the meaning as indi...
|
|
WO/2022/084334A1 |
The present invention relates to compositions comprising as component (A) at least one compound of formula (I), or an agrochemically acceptable salt thereof wherein R1 is (II) or (III) and, as component (B), at least one compound, or agr...
|
|
WO/2022/083703A1 |
This disclosure relates to LPA antagonists of Formula (I) : including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/087326A1 |
Provided herein are Heterocyclic Compounds of formula (I), formula (II), formula (III), formula (IlIa), formula (Mb), formula (IIIc), formula (Hid), formula (IV), formula (IVa), formula (IVb), and formula (IVc), and pharmaceutically acce...
|
|
WO/2022/084479A1 |
The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction,...
|
|
WO/2022/082305A1 |
The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the am...
|
|
WO/2022/086892A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2022/087433A1 |
The present disclosure relates to compounds of formula I that are capable of inhibiting creatine kinase. The present disclosure also relates to methods of treating cancer, such as hematological malignancies.
|
|
WO/2022/083853A1 |
The present invention relates to novel free fatty acid receptor (FFAR) agonists (I), in particular agonists of FFAR1, and to the use of said FFAR agonists as medicaments, in particular for treatment and/or prevention of conditions or dis...
|
|
WO/2022/084447A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R3, R4a, R4b, R4c, R4d, R4f, X1, X2 have the meaning as indicated in ...
|
|
WO/2022/086920A1 |
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...
|
|
WO/2022/084331A2 |
The present disclosure provides novel piperidine- and guanosine-derived ligands that bind specifically to asialoglycoprotein receptor (ASGPR) and nucleotide analogs conjugated thereto that can be incorporated into oligonucleotides, inclu...
|
|
WO/2022/078309A1 |
Provided are a substituted bis(pyridin-2-yl)amine derivative represented by formula (I), a pharmaceutically acceptable salt, solvate, stereoisomer, prodrug and pharmaceutical composition thereof, and a medical application thereof. The de...
|
|
WO/2022/080696A1 |
Provided is a high-refractive-index benzazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
|
|
WO/2022/077161A1 |
Provided is a Compound for modulating the activity of FXR having a structure of formula (I), a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, wherein M, Q, T, W, Y and Z are independently selected from N and O, and...
|
|
WO/2022/078971A1 |
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregat...
|
|
WO/2022/078414A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
|
|
WO/2022/078306A1 |
The present invention relates to the technical field of organic synthesis and chemical catalysis. Disclosed are a large steric hinderance palladium-nitrogen-heterocyclic carbene complex, a preparation method for same, applications of sam...
|
|
WO/2022/078927A1 |
The invention describes a process for reworking of a crystallization product comprising drying and homogenization. The crystallization product is crystalline [5-(methylsulfonyl)-2- {[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-...
|
|
WO/2022/081807A1 |
The present invention provides acyl sulfonamide compounds of general formula (I): in which R1, R2, R3, R4, R5, R6· Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for pre...
|
|
WO/2022/076764A1 |
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2022/073969A1 |
The present invention relates to compounds of Formula (I), wherein Ar1, A, B, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceut...
|
|
WO/2022/073905A1 |
This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
|
|
WO/2022/076662A1 |
The present disclosure relates to compounds of Formula (I); and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/073904A1 |
This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
|
|
WO/2022/076627A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases,...
|
|
WO/2022/074143A1 |
The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxi...
|
|
WO/2022/076417A1 |
A method of treating and/or preventing disease wherein retinal pigment epithelium, including administering compound of formula (I) or pharmaceutically acceptable salt, racemic mixture, corresponding enantiomer or, if applicable, correspo...
|
|
WO/2022/074103A1 |
The present invention relates to new compounds of formula (I): as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases a...
|
|
WO/2022/070023A1 |
An object of the present disclosure is to provide a piperazine compound or the salt thereof that controls pests. The present disclosure provides a piperazine compound represented by Formula (I), or a salt thereof, wherein R1 represents a...
|
|
WO/2022/069953A1 |
The present invention relates to development of novel (S)-3 -(5 -fluoropyridin-2-yl)-5 -(piperidin- 3-yl)- 1,2,4-oxadiazole derivatives. It particularly relates to the development of novel compounds of (S)-3 -(5 -fluoropyridin-2-yl)-5 -(...
|
|
WO/2022/069509A1 |
The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1- yl)-acetamide derivatives as potent inhibitors of transforming growth factor-β receptor I, (also named activin receptor-like kinase 5) (TGFβRI)/ALK5. O...
|
|
WO/2022/072741A1 |
The present invention relates to novel compounds of formula (la), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/ TAZ-TEAD transcription, yet more in pa...
|
|
WO/2022/071777A1 |
The present invention relates to a medicinal use of compounds having inhibitory activity against pendrin, and provides a compound represented by chemical formula 1 or 2, below, an E- or Z-isomer thereof, an optical isomer thereof, a prec...
|
|
WO/2022/068917A1 |
Provided is a compound as an Akt kinase inhibitor. The present invention specifically relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition contain...
|
|
WO/2022/063784A1 |
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods fo...
|
|
WO/2022/065894A1 |
The present invention relates to a novel quinazoline derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and use thereof. A novel benzoimidazole derivative or a pharmaceutically-acceptable salt thereof, according to ...
|
|
WO/2022/063205A1 |
An aryl formamide compound, a preparation method for same, and medicinal uses thereof. Specifically, related are a compound as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the compoun...
|
|
WO/2022/066917A1 |
Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein L1, R1, R2, R3, R4, R6, R7, R8, R9 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing...
|
|
WO/2022/063094A1 |
A series of tetrahydroisoquinoline derivatives and the crystal forms thereof. Specifically disclosed are a compound as represented by formula (VII), a crystal form thereof, and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/062597A1 |
A thermally activated delayed fluorescence material and the use thereof. The thermally activated delayed fluorescence material has a diquinoxaline structure, is new in structure, has good photoelectric properties, and is suitable as a li...
|
|
WO/2022/063152A1 |
Provided are compounds of Formula I, compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).
|
|
WO/2022/063858A1 |
The invention provides immunomodulatory compounds, adjuvant compositions comprising thereof, immunogenic compositions comprising thereof and uses of immunomodulatory compounds as adjuvants in vaccination, for increasing the immune respon...
|
|
WO/2022/060196A1 |
The present invention relates to a pharmaceutical composition comprising a compound of the present invention, an isomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient ...
|
|
WO/2022/057932A1 |
A carbonyl heterocyclic compound as represented by formula II or a pharmaceutically acceptable salt thereof. The carbonyl heterocyclic compound can be used as a compound having a targeted lanthionine synthetase C-like protein 2 pathway; ...
|
|
WO/2022/057672A1 |
Disclosed in the present invention is an FXR (farnesoid X receptor) small molecule agonist and a preparation method therefor, the structure thereof being as shown in formula I. The definitions of the substituent groups are as set forth i...
|
|
WO/2022/057142A1 |
Steroid synthetase inhibitors and the therapeutic use thereof, which belong to the field of medicines. The compounds for use as drugs have the effect of inhibiting steroid synthetases with a high inhibition rate, and can be used as drugs...
|
|
WO/2022/058878A1 |
The present invention relates to a compound of formula (I), Formula (I), wherein, R1, R1a, R2, W, R3, R4, R5, A, R6, R7 and R8 are as defined in the detailed description and to a process for preparing the compound of formula (I). The pre...
|
